Annett Linge

List of Publications by Year
in descending order

74 papers	2,252 citations	279487 23 h-index	223531 46 g-index
79 all docs	79 docs citations	79 times ranked	4169 citing authors

#	Article	IF	Citations
1	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. Radiotherapy and Oncology, 2022, 167, 300-307.	0.3	5
2	Plasticity within Aldehyde Dehydrogenase–Positive Cells Determines Prostate Cancer Radiosensitivity. Molecular Cancer Research, 2022, 20, 794-809.	1.5	8
3	Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma. Cancers, 2022, 14, 1677.	1.7	7
4	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC – Hypothesis generation on a multicentre cohort of the DKTK-ROG. Radiotherapy and Oncology, 2022, 169, 8-14.	0.3	5
5	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. Radiotherapy and Oncology, 2022, 171, 91-100.	0.3	4
6	Importance of long-term follow up to address long-term effectiveness and toxicity of radiotherapy. Radiotherapy and Oncology, 2022, 170, 1-3.	0.3	1
7	Assessment of gene expressions from squamous cell carcinoma of the head and neck to predict radiochemotherapy-related xerostomia and dysphagia. Acta Oncológica, 2022, 61, 856-863.	0.8	4
8	A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. Cancers, 2022, 14, 3031.	1.7	2
9	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. Pharmacogenomics Journal, 2021, 21, 37-46.	0.9	6
10	Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. Clinical and Translational Radiation Oncology, 2021, 26, 62-70.	0.9	8
11	The Pluripotency Transcription Factor Oct4 Contributes to Head and Neck Squamous Cell Carcinoma Radioresistance via Regulation of DNA Repair and the Stem Cell Phenotype. Medical Sciences Forum, 2021, 3, .	0.5	0
12	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. Theranostics, 2021, 11, 7844-7868.	4.6	70
13	Do We Need Complex Image Features to Personalize Treatment of Patients with Locally Advanced Rectal Cancer?. Lecture Notes in Computer Science, 2021, , 775-785.	1.0	2
14	Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas. Cancers, 2021, 13, 1865.	1.7	9
15	Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L. Oncogene, 2021, 40, 4214-4228.	2.6	27
16	Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiation Oncology, 2021, 16, 141.	1.2	9
17	OC-0062 Potential predictive biomarkers for Nimorazole-modified radiochemotherapy in head and neck cancer. Radiotherapy and Oncology, 2021, 161, S37-S38.	0.3	0
18	OC-0638 Integrated radiogenomics analyses for outcome prognosis in patients with locally advanced HNSCC. Radiotherapy and Oncology, 2021, 161, S503-S504.	0.3	0

#	Article	IF	Citations
19	OC-0277 A 6-gene signature for loco-regional control prognosis in HNSCC patients treated by PORT-C. Radiotherapy and Oncology, 2021, 161, S186-S187.	0.3	0
20	Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma. Clinical Cancer Research, 2021, 27, 1351-1360.	3.2	15
21	Tumor DNA–Methylome derived Epigenetic Fingerprint Identifies HPV –negative Head and Neck Patients at Risk for Locoregional Recurrence after Postoperative Radiochemotherapy. International Journal of Cancer, 2021, 150, 603.	2.3	2
22	Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). Cancers, 2021, 13, 5595.	1.7	4
23	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. Scientific Reports, 2020, 10, 15625.	1.6	34
24	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. Cancers, 2020, 12, 3047.	1.7	19
25	PRDX3 is associated with metastasis and poor survival in uveal melanoma. Journal of Clinical Pathology, 2020, 73, 408-412.	1.0	11
26	Specific requirements for translation of biological research into clinical radiation oncology. Molecular Oncology, 2020, 14, 1569-1576.	2.1	6
27	Comparison of GeneChip, nCounter, and Real-Time PCR–Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. Journal of Molecular Diagnostics, 2020, 22, 801-810.	1.2	10
28	Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma. Cancers, 2020, 12, 871.	1.7	9
29	PD-0066: A 24-miRNA signature predicting HPV status in head and neck cancer. Radiotherapy and Oncology, 2020, 152, S27-S28.	0.3	0
30	PO-1540: Radiomic models for validation in patients with locally advanced HNSCC treated with primary RTCx. Radiotherapy and Oncology, 2020, 152, S832-S833.	0.3	0
31	SLC3A2/CD98hc, autophagy and tumor radioresistance: a link confirmed. Autophagy, 2019, 15, 1850-1851.	4.3	56
32	OC-0496 Deep-learning based estimation of locoregional control for patients with locally advanced HNSCC. Radiotherapy and Oncology, 2019, 133, S254-S255.	0.3	0
33	A Methylome Classifier Identifies Patients at Risk for Locoregional Recurrence after Adjuvant Radiochemotherapy in HPV-DNA negative HNSCC: a Multicenter Trial of the German Cancer Consortium- Radiation Oncology Group (DKTK-ROG). International Journal of Radiation Oncology Biology Physics, 2019, 105, S17-S18.	0.4	0
34	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. Clinical Cancer Research, 2019, 25, 3152-3163.	3.2	53
35	Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group. European Journal of Cancer, 2019, 116, 67-76.	1.3	58
36	Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy. Clinical and Translational Radiation Oncology, 2019, 16, 40-47.	0.9	32

#	Article	IF	Citations
37	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. Radiotherapy and Oncology, 2019, 135, 43-50.	0.3	25
38	Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma. Clinical and Translational Radiation Oncology, 2019, 15, 42-45.	0.9	10
39	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. Clinical Cancer Research, 2019, 25, 1505-1516.	3.2	67
40	Connective tissue growth factor (CTGF) methylation status is associated with prognosis of patients with head and neck squamous cell carcinoma (HNSCC) treated with radiochemotherapy (RCHT): A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. Journal of Clinical Oncology, 2019, 37, 6050-6050.	0.8	0
41	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. Radiotherapy and Oncology, 2018, 127, 27-35.	0.3	17
42	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. Clinical Cancer Research, 2018, 24, 1364-1374.	3.2	45
43	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. Radiotherapy and Oncology, 2018, 126, 125-131.	0.3	24
44	Heat shock protein 70 and tumorâ€infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTKâ€ROG). International Journal of Cancer, 2018, 142, 1911-1925.	2.3	50
45	PO-119 Accelerated glutamine metabolism is conferring radioresistance to prostate cancer. ESMO Open, 2018, 3, A272-A273.	2.0	0
46	OC-0152: Glutamine metabolism as potential biomarker and target for prostate cancer radiosensitization. Radiotherapy and Oncology, 2018, 127, S76-S77.	0.3	1
47	OC-0324: Immune contexture in SCCHN and outcome after chemoradiotherapy in an uni- and multicentric cohort. Radiotherapy and Oncology, 2018, 127, S172-S173.	0.3	0
48	Subjugation of TGFÎ² Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining. Clinical Cancer Research, 2018, 24, 6001-6014.	3.2	71
49	Discovery of a reliable and robust methylome classifier of HPV driven head and neck cancer with favorable response to chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. Journal of Clinical Oncology, 2018, 36, 6019-6019.	0.8	2
50	Interference between mutational load, immune signatures and outcome in patients with head and neck cancer treated with definitive chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. Journal of Clinical Oncology, 2018, 36, 6047-6047.	0.8	2
51	Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Advanced Drug Delivery Reviews, 2017, 109, 63-73.	6.6	247
52	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). International Journal of Cancer, 2017, 141, 594-603.	2.3	91
53	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. Scientific Reports, 2017, 7, 13206.	1.6	163
54	PO-0619: Comparison of a nanoString and RNA microarray gene signature predicting LRC after PORT-C in HNSCC. Radiotherapy and Oncology, 2017, 123, S323-S324.	0.3	0

#	ARTICLE	IF	CITATIONS
55	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. Clinical and Translational Radiation Oncology, 2017, 5, 28-36.	0.9	16
56	EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models. Radiotherapy and Oncology, 2017, 124, 496-503.	0.3	21
57	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2016, 121, 364-373.	0.3	130
58	Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy. Clinical and Translational Radiation Oncology, 2016, 1, 19-26.	0.9	22
59	The Role of Cancer Stem Cells in Tumour Radioresponse. , 2016, , 43-74.		0
60	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(â˜) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. Clinical Cancer Research, 2016, 22, 2639-2649.	3.2	127
61	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). International Journal of Cancer, 2016, 138, 171-181.	2.3	184
62	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. Radiotherapy and Oncology, 2016, 118, 350-358.	0.3	62
63	Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation. European Journal of Cancer, 2016, 57, 78-86.	1.3	62
64	Corrigendum to â€œHPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)â€•[Radiother. Oncol. 113 (2014) 317â€“323]. Radiotherapy and Oncology, 2015, 114, 419.	0.3	0
65	Mutational patterns of HPV+ and HPV- squamous cell carcinomas of the head and neck (SCCHN) and their interference with outcome after adjuvant chemoradiation: A multicenter biomarker study of the German Cancer Consortium Radiation Oncology Group.. Journal of Clinical Oncology, 2015, 33, 6006-6006.	0.8	3
66	HPV and beyond-looking out for biomarkers for distinguishing the good prognosis from the bad prognosis group in locally advanced and clinically high risk HNSCC. Annals of Translational Medicine, 2015, 3, 255.	0.7	2
67	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiotherapy and Oncology, 2014, 113, 317-323.	0.3	141
68	Identification and Functional Validation of RAD23B as a Potential Protein in Human Breast Cancer Progression. Journal of Proteome Research, 2014, 13, 3212-3222.	1.8	28
69	Differential Expression of Fourteen Proteins between Uveal Melanoma from Patients Who Subsequently Developed Distant Metastases versus Those Who Did Not. , 2012, 53, 4634.		54
70	Bleomycin treatment of A549 human lung cancer cells results in association of MGr1-Ag and caveolin-1 in lipid rafts. International Journal of Biochemistry and Cell Biology, 2011, 43, 98-105.	1.2	10
71	Increased P2X7R expression in atrial cardiomyocytes of caveolin-1 deficient mice. Histochemistry and Cell Biology, 2010, 134, 31-38.	0.8	16
72	Characterization of the molecular interaction between caveolin-1 and the P2X receptors 4 and 7 in E10 mouse lung alveolar epithelial cells. International Journal of Biochemistry and Cell Biology, 2008, 40, 2230-2239.	1.2	29

#	Article	IF	Citations
73	Downregulation of caveolin-1 affects bleomycin-induced growth arrest and cellular senescence in A549 cells. International Journal of Biochemistry and Cell Biology, 2007, 39, 1964-1974.	1.2	42
74	Bleomycin induces caveolin-1 and -2 expression in epithelial lung cancer A549 cells. Anticancer Research, 2007, 27, 1343-51.	0.5	10